
|Articles|March 3, 2010
NicOx partners with Bausch & Lomb for its candidate glaucoma drug
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
Advertisement
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
2
Why ST-100 is expanding from dry eye into corneal wound healing
3
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
4
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
5











